不同血供分型对肝动脉化疗栓塞术治疗肝血管瘤患者疗效的影响

摘要/Abstract

摘要： 目的探讨不同血供分型对肝动脉化疗栓塞术治疗肝血管瘤患者疗效的影响,为临床治疗肝血管瘤提供依据。方法回顾性分析2019年2月至2024年2月本院收治的行肝动脉化疗栓塞术治疗肝血管瘤患者102例,根据不同血供分型,将其分为乏血供型组(34例)、中等血供型组(34例)和富血供型组(34例),比较3组临床疗效、血生化指标以及并发症发生情况。结果术后1周,富血供型组的临床疗效为88.24%,高于中等血供型组和乏血供型组(64.71%、44.12%,P<0.05)。富血供型组的博来霉素碘化油用量为(12.02±1.01)mL,高于中等血供型组和乏血供型组[分别为(7.58±1.05)mL、(4.85±1.02)mL,均P<0.05]。与术前比,术后1周3组血清丙氨酸氨基转移酶、总胆红素、直接胆红素水平均上升,富血供型组分别为(101.25±20.45)U/L、(11.65±1.02)μmoL/L、(10.58±1.23)μmoL/L,低于中等血供型组(142.35±21.55)U/L、(13.69±1.62)μmoL/L、(13.25±1.14)μmoL/L与乏血供型组[分别为(168.56±22.36)U/L、(15.56±1.58)μmoL/L、(15.25±1.02)μmoL/L,均P<0.05]。富血供型组并发症发生率为11.76%,低于中等血供型组、乏血供型组(分别为14.71%、17.65%,均P>0.05)。结论经肝动脉化疗栓塞术治疗后,肝血管瘤富血供型的临床疗效更高,其临床指标改善,肝功能优化,同时不同血供分型的安全性均良好。

关键词: 肝动脉化疗栓塞术, 肝血管瘤, 血供分型

Abstract: Objective To explore the influence of different blood supply typing on the efficacy of hepatic artery chemoembolization in the treatment of hepatic hemangioma patients, and to provide a basis for clinical treatment of hepatic hemangioma. Methods In this retrospective study, 102 patients with hepatic hemangiomas treated with hepatic artery chemoembolization admitted to our hospital during February 2019 to February 2024 were included. According to the different blood supply types, the patient were divided into a hupovascular group (34 cases), a moderately vascular group (34 groups), and a hupervascular group (34 cases). The clinical efficacy, blood biochemical indicators and incidence of complications were compared among three groups. Results At 1 week postoperatively, the clinical efficacy of the blood-rich group was 88.24%, which was higher than that of the intermediate blood-supply group and the lack of blood-supply group (64.71% and 44.12%, P<0.05). The amount of bleomycin-iodized oil in the rich blood supply group was (12.02±1.01) mL, which was higher than that in the intermediate blood supply group and the lack of blood supply group [(7.58±1.05) mL and (4.85±1.02) mL, respectively, P<0.05]. Compared with the preoperative period, serum ghrelin, total bilirubin, and direct bilirubin levels increased in all three groups at 1 week postoperatively, but were lower in the rich blood supply group at (101.25±20.45) U/L, (11.65±1.02) μmoL/L, and (10.58±1.23) μmoL/L than those of the moderate blood supply group at (142.35±21.55) U/L, (13.69 ± 1.62) μmoL/L, (13.25 ± 1.14) μmoL/L in the spent blood supply group [168.56 ± 22.36) U/L, (15.56 ± 1.58) μmoL/L, (15.25 ± 1.02) μmoL/L, respectively, P<0.05]. Conclusion After treatment by hepatic artery chemoembolization, the clinical efficacy of hepatic hemangioma rich blood supply type was higher, which could improve their clinical indexes and optimize liver function, and the safety of different blood supply subtypes is good.

Key words: Transcatheter arterial chemoembolization, Hepatic hemangioma, Blood supply typing

姚煜, 徐春阳, 任健吾. 不同血供分型对肝动脉化疗栓塞术治疗肝血管瘤患者疗效的影响[J]. 肝脏, 2025, 30(9): 1254-1257.

YAO Yu, XU Chun-yang, REN Jian-wu. Influence of different blood supply typing on the efficacy of hepatic artery chemoembolization in the treatment of patients with hepatic hemangioma[J]. Chinese Hepatolgy, 2025, 30(9): 1254-1257.

/ 推荐

参考文献

[1] 邵天胤, 余俊, 周洪浩, 等. 腹腔镜肝切除术与腹腔镜微波消融术治疗肝血管瘤的有效性和安全性研究[J]. 肝胆胰外科杂志,2023,35(11): 660-667.
[2] Aziz H, Brown Z J, Baghdadi A, et al. A comprehensive review of hepatic hemangioma management[J]. J Gastrointest Surg,2022,26(9):1998-2007.
[3] Eghlimi H, Arasteh P, Azade N. Orthotopic liver transplantation for management of a giant liver hemangioma: a case report and review of literature[J]. BMC Surg,2020,20(1):142.
[4] Boccatonda A, D'Ardes D, Cocco G, et al. The case of a liver adenoma that looked like a hemangioma[J]. Radiol Case Rep,2023,18(3):1024-1028.
[5] 韩廷超, 王忠, 申梦圆, 等. 血供类型对肝血管瘤患者介入栓塞术后3年疗效的影响[J]. 肝脏,2023,28(7):833-836.
[6] 王儒发, 林成, 岑炳奎. 经肝动脉栓塞术治疗不同血供特点的肝血管瘤患者的疗效分析[J]. 实用癌症杂志,2020,35(8):1331-1334.
[7] Albitar H A H, Iyer V. Giant liver hemangioma with kasabach-merritt syndrome[J]. Am J Med,2020,133(1):56-57.
[8] Rogers T, Shah N, Mauro D, et al. Anastomosing hemangioma of the liver: an unusual variant in abdominal MRI imaging[J]. Radiol Case Rep,2022,17(12):4889-4892.
[9] Philipp J, Schmidberger J, Schlingeloff P, et al. Differentiation of hepatic alveolar echinococcosis with a hemangioma-like pattern compared to typical liver hemangioma using contrast-enhanced ultrasound: a pilot study[J]. Infection,2023,51(1):159-168.
[10] Bonatti M, Valletta R, Corato V, et al. I thought it was a hemangioma! A pictorial essay about common and uncommon liver hemangiomas' mimickers[J]. Insights Imaging,2024,15(1): 228.
[11] Zhang W, Liu J, Zhang Z, et al. Perioperative outcomes of robot-assisted versus laparoscopic liver resection for cavernous hemangioma: a propensity score matching study[J]. Surg Endosc,2023,37(6):4505-4516.
[12] Sözel H, YƷlmaz F. Primary splenic angiosarcoma with liver metastasis caused by malign transformation of hemangioma: a case report and literature review[J]. J Gastrointest Cancer,2021,52(3):1086-1089.
[13] Boey C Y, Mohamed Aslum Khan F, Amir Hassan S Z. Giant liver hemangioma mimicking a hydronephrotic kidney on 99mtc-dtpa scintigraphy[J]. Clin Nucl Med,2021,46(1):88-89.
[14] Wu X F, Bai X M, Yang W, et al. Differentiation of atypical hepatic hemangioma from liver metastases: diagnostic performance of a novel type of color contrast enhanced ultrasound[J]. World J Gastroenterol,2020,26(9):960-972.
[15] Takayama Y, Nishie A, Okamoto D, et al. Differentiating liver hemangioma from metastatic tumor using t2-enhanced spin-echo imaging with a time-reversed gradient-echo sequence in the hepatobiliary phase of gadoxetic acid-enhanced mr imaging[J]. Magn Reson Med Sci,2022,21(3):445-457.
[16] Shankar S, Rammohan A, Kulaseharan V H, et al. Liver transplantation for rapidly progressive giant hepatic hemangioma with diffuse hemangiomatosis[J]. Exp Clin Transplant,2021,19(10):1106-1109.
[17] Gholami R, Soltani M, Salarieh N, et al. A liver-derived vascular lesion: hepatic hemangioma or hepatic epithelioid hemangioendothelioma?[J]. Middle East J Dig Dis,2023,15(3):210-213.
[18] Amsiguine N, Imrani K, El Houss S, et al. Kasabach-merritt syndrome complicating a giant hemangioma of the liver: a case report[J]. Radiol Case Rep,2023,18(6):2183-2185.
[19] 姚煜, 戴峰, 徐春阳. 肝血管瘤血供类型对经肝动脉介入治疗效果的影响[J]. 肝脏,2020,25(6):591-594.
[20] 梅国勋, 孙静涛, 杨琦, 等. 经动脉介入栓塞治疗不同血供类型的婴幼儿肝血管瘤效果及其影响因素分析[J]. 中国小儿血液与肿瘤杂志,2023,28(5):283-287.